228 related articles for article (PubMed ID: 17299395)
1. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
6. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
7. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
8. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
Colby C; Koziol S; McAfee SL; Yeap B; Spitzer TR
Bone Marrow Transplant; 2002 Mar; 29(6):467-72. PubMed ID: 11960264
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
10. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
12. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
Bailey DB; Rassnick KM; Dykes NL; Pendyala L
Am J Vet Res; 2009 Jun; 70(6):770-6. PubMed ID: 19496668
[TBL] [Abstract][Full Text] [Related]
14. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
16. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
17. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
19. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]